Popular Articles

Common Food Dye May Hold Promise In Treating Spinal Cord Injury
A common food additive that gives M&Ms and Gatorade their blue tint may offer promise for preventing the additional and serious secondary damage that immediately follows a traumatic injury to the spinal cord. In an article published online in the Proceedings of the National Academy of Sciences, researchers report that the compound Brilliant Blue G (BBG) stops the cascade of molecular events that cause secondary damage to the spinal cord in the hours following a spinal cord injury, an injury known to expand the injured area in the spinal cord and permanently worsen the paralysis for patients.

At Ohio Town Hall, Obama Says Congressional Delay Is 'Okay'
President Obama rallied support for health care at a town hall meeting in Shaker Heights, Ohio, on Thursday, despite news of a legislative delay in the Senate.
News of the day
Tiller's Patients, Not Critics, Should Be Ones To 'Define His Memory,' Opinion Piece Says
In a "portrayal that defied logic," George Tiller -- the Kansas abortion provider who was murdered last month -- has been depicted "on Web sites, TV and radio talk shows and in legislative hearings as the reckless "abortionist," willing to euthanize babies close to birth just so the mother could fit into a prom dress or attend a rock concert," Barbara Shelly, a member of the Kansas City Star editorial board, writes in a Star opinion piece. She asks, "Would someone in the third trimester of pregnancy travel to the heart of Kansas and pay a $6,000 fee just to fit into a size six party dress?" Shelly adds that the "overwhelming majority of the 250 to 300 women a year" that sought abortions from Tiller in the second and third trimesters had planned their pregnancies. She profiles a Missouri college professor, pregnant with twins, who traveled to Tiller"s clinic with her husband to obtain an abortion after an amniocentesis revealed that neither fetus would survive and that she faced potentially life-threatening complications if the pregnancy continued. Shelly writes that the woman and others like her went to Tiller "heartbroken and afraid, carrying fetuses with malfunctioning kidneys, missing organs and syndromes certain to cause death in the womb or soon after birth." A smaller number were survivors of rape and incest, including young girls, according to Shelly. The "prom queen who talked her way into a late-term abortion" is a "creation of Tiller"s enemies," Shelly writes, concluding that the "real people" affected by his death are the "thousands who wrote the notes that now serve as a memorial wall to a fallen physician. They are the ones who should define his memory" (Shelly, Kansas City Star, 6/9).
Public Health

Green Tea Compound May Block A Key Process In Alzheimer's Development

Researchers affiliated with Natura Therapeutics, Inc., Tampa, Florida, and the University of South Florida (USF) have jointly received a one-year, $110,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health"s (NIH) National Center for Complementary and Alternative Medicine to continue studying TeaMem™, a compound made from green tea. TeaMem™ holds promise for preventing and treating Alzheimer"s disease (AD), a disease that the Alzheimer"s Association says today affects as many as 5.2 million Americans. The most recent grant follows two other NIH grants to develop and evaluate TeaMem™ -- a $160,000 grant for 2007-2008 and a $140,000 grant for 2008-2009. The research conducted under these three grants was also supported through matching funds from the Florida High Tech Corridor Matching Grants Research Program. According to Jun Tan, M.D., Ph.D., a professor in the USF Department of Psychiatry and Behavioral Medicine, and one of the grant"s principal investigators, the grant will be used to investigate the role of TeaMem™ in opposition to cleavage of the amyloid precursor protein protelysis (APP) into Abeta peptides and resultant cerebral amyloidosis, a process identified as a key feature in AD pathology. "Our recent findings suggest that strategies that promote non-amyloidogenic/alpha-secretase APP processing may have significant potential for the treatment of AD," said Tan. This SBIR grant, the most recent of three NIH grants, allows the continuing development of TeaMem™ and its evaluation in the test tube (in vitro). The latest grant provides for testing in vitro and in the body (in vivo) using mouse models to evaluate the effects of TeaMem™. Early tests will evaluate TeaMem™ in promoting non-amyloidogenic APP alpha-secretase proteolysis and then examine its therapeutic and preventive effects on AD pathology and cognitive impairment. "We expect to clearly define this non-amyloidogenic mechanism and identify the potential molecular drug targets essential for formulating novel, effective treatments against AD," explained Cyndy D. Sanberg, Ph.D., senior vice president of Natura Therapeutics, Inc. and the other PI on the grant. Tests, including cognitive tests, will use mouse models for oral administration of TeaMem™ to a prophylactic treatment group that will be compared to a second group with AD-like pathology. Groups will be compared for the effect of reducing AD-like pathology and behavioral impairment. The studies, said Tan, could lay the groundwork for AD clinical trials in humans in the near future. In their 2008 report, the Alzheimer"s Association (http://www.alz.org) noted that AD was the nation"s sixth leading cause of death and predicts 10 million baby boomers will develop AD. The direct and indirect costs of AD exceed $148 billion annually, said the Association. Dr. Jun Tan University of South Florida Health


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):